LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)

Organon

Status and phase

Completed

Phase 4

Conditions

Hypertension

Treatments

Drug: losartan potassium

Drug: Comparator: carvedilol (+) hydrochlorothiazide

Drug: Comparator: losartan (+) hydrochlorothiazide (HCTZ)

Drug: Comparator: carvedilol

Study type

Interventional

Funder types

Industry

Identifiers

NCT00496834

0954-330

2007_015

Details and patient eligibility

About

The primary objective of this study is to evaluate efficacy, arterial stiffness measured by Pulse Wave Velocity (PWV) of Losartan potassium group compared to Carvedilol group after 24 weeks of treatment in patients with the essential hypertension.

Enrollment

201 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or Female adults, 18 years or over
Essential Hypertension with mean SBP (systolic blood pressure) ≥ 140 mm Hg or mean DBP (diastolic blood pressure) ≥ 90 mm Hg* when blood pressure is measured at Visit 1(week -2) and at Visit 2(week 0).

If diabetes patients, mean SBP ≥ 130 mm Hg or mean DBP ≥ 80 mm Hg (Mean of blood pressure values measured consecutively at least 2 minutes apart)

Patient who is willing to, and is able to sign the informed consent form

Exclusion criteria

Patient Is Pregnant Or Breastfeeding, Or Expecting To Conceive Within The Projected Duration Of The Study
Patient Has Known Or Suspected Secondary Hypertension Of Any Etiology
Patient has history of malignant hypertension
Patient has history of cerebrovascular accident (cerebral infarction) or myocardiac infarction within the last 6 months
Patient takes antihypertensive drugs